RESUMO
ß-Amyloid (Aß) accumulation in the brain is widely accepted to be critical to the development of Alzheimer's disease (AD). Current efforts at reducing toxic Aß40 or 42 have largely focused on modulating γ-secretase activity to produce shorter, less toxic Aß, while attempting to spare other secretase functions. In this paper we provide data that offer the potential for a new approach for the treatment of AD. The method is based on our previous findings that the production of Aß from the interaction between the ß-amyloid precursor protein (APP) and Presenilin (PS), as part of the γ-secretase complex, in cell culture is largely inhibited if the entire water-soluble NH2-terminal domain of PS is first added to the culture. Here we demonstrate that two small, non-overlapping water-soluble peptides from the PS-1 NH2-terminal domain can substantially and specifically inhibit the production of total Aß as well as Aß40 and 42 in vitro and in vivo in the brains of APP transgenic mice. These results suggest that the inhibitory activity of the entire amino terminal domain of PS-1 on Aß production is largely focused in a few smaller sequences within that domain. Using biolayer interferometry and confocal microscopy we provide evidence that peptides effective in reducing Aß give a strong, specific and biologically relevant binding with the purified ectodomain of APP 695. Finally, we demonstrate that the reduction of Aß by the peptides does not affect the catalytic activities of ß- or γ-secretase, or the level of APP. P4 and P8 are the first reported protein site-specific small peptides to reduce Aß production in model systems of AD. These peptides and their derivatives offer new potential drug candidates for the treatment of AD.
